“木头姐”2026战略：押注基因编辑，抛售消费科技

Core Insights - Cathie Wood's ARK Invest is shifting its investment focus towards early-stage biotechnology companies while reducing exposure to consumer technology, diagnostics, and space technology sectors [1][2] Group 1: Biotechnology Investments - ARK Invest has significantly increased its holdings in gene editing and genomics, particularly buying over 195,000 shares of Beam Therapeutics (BEAM.US), with a market value of approximately $5.4 billion [1] - The firm also acquired about 236,000 shares of Intellia Therapeutics (NTLA.US), which utilizes CRISPR technology for gene repair, aligning with its strategic focus [2] - Additional investments include over 423,000 shares of Pacific Biosciences of California (PACB.US) and 101,000 shares of Twist Bioscience (TWST.US), emphasizing a commitment to genomic discoveries and precision medical tools [2] Group 2: Adjustments in Holdings - ARK is systematically adjusting its portfolio in the medical and technology sectors, reducing its stake in Ionis Pharmaceuticals (IONS.US) by 26,645 shares and scaling back on Natera (NTRA.US) and Guardant Health (GH.US) [3] - The flagship ARK Innovation ETF has executed structural adjustments, selling over 72,000 shares of Roku (ROKU.US) and more than 29,000 shares of Shopify (SHOP.US) [4] - Despite selling over 633,000 shares of Tesla (TSLA.US), it remains the largest holding in ARK's portfolio, which has outperformed major U.S. benchmark indices [4]